Report #2870594

Received Nov 4, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 76 yrs
State: IA
Recovered: Unknown
Vaccinated: Oct 21, 2025
Onset: Oct 21, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	2	G347X	—

Symptoms (1)

Extra dose administered

Symptom narrative

Second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a elderly female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number G347X, expiry date 12-DEC-2026) for prophylaxis. Previously administered products included Arexvy (Received 1st dose of Shingrix vaccine in SEP-2024). On 21-OCT-2025, the patient received the 2nd dose of Arexvy. On 21-OCT-2025, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: Second dose). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 21-OCT-2025 A patient got a second shot of Arexvy on 21-OCT-2025. First dose was administered back in September 2024. The reporter knew that is a onetime thing, but was curious about adverse effects.